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Paradoxical Effects of Atorvastatin on Renal Tubular Cells
An Experimental Investigation
Zahra Hasanpour,1,2 Hamid Nasri,1,2 Mahmoud Rafieian-Kopaei,3 
Ali Ahmadi,4 Azar Baradaran,5 Parto Nasri,1 Mehdi Nematbakhsh1
Introduction. Atorvastatin has antioxidant activity and has been 
reported to increase blood antioxidant capacity. This study aimed to 
evaluate the effect of different doses of atorvastatin on gentamicin-
induced kidney injury. 
Materials and Methods. In this experimental study, 30 male Wistar 
rats were designated into 6 equal groups for a 7-day period of 
intraperitoneal injections of gentamicin and atorvastatin. Group 
1 received gentamicin, 80 mg/kg. Group 2 received phosphate 
buffer as the vehicle of atorvastatin. All rats in groups 3, 4, and 
5 received gentamicin, 80 mg/kg/d, and then, after a 1-hour 
interval, atorvastatin was injected for 7 days as follow: group 3, 
10 mg/kg/d; group 4, 50 mg/kg/d; and group 5, 150 mg/kg/d. 
Rats in group 6 received only 150 mg of atorvastatin. On the 8th 
day, blood samples were collected for evaluation of creatinine 
and blood urea nitrogen levels, and the animals’ kidneys were 
dissected out for histopathological examinations.
Results. Morphological damages to the tubular cells in groups 3 and 
4 were less than the those in groups 1 and 5. Injuries to the renal 
tubular cells in the rats of group 5 (gentamicin and atorvastatin, 
150 mg/kg/d) and in group 6 (atorvastatin 150 mg/kg/d alone) 
were more extensive than those in group 1. 
Conclusions. The none–dose-dependent effect of atorvastatin in 
inducing renal tubular cell protection and renal tubular toxicity 
of atorvastatin in higher dose suggest administration of low-dose 
atorvastatin in critical conditions associated with renal tubular 
cell protection.
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INTRODUCTION
Atorvastatin is one of the most frequently 
and extensively prescribed 3-hydroxy-3-methyl-
glutaryl-CoA reductase inhibitors which was 
first manufactured in 1985 for the treatment of 
hyperlipidemia.1,2 Various studies have detected 
that atorvastatin has the capability to directly bind 
and metabolize reactive oxygen species resulting 
in reduction of intracellular reactive oxygen 
species levels.2-4 Also, atorvastatin is able to act 
in the kidney as a potent free radical scavenger 
and inhibit mitogen-activated protein kinase and 
nuclear factor kappa B. It also inhibits signaling 
pathways activation by reactive oxygen species 
and hence prevents tubule cell apoptosis induced 
by gentamicin.5-9 
In general, statins may exert lipid-independent 
benefits against kidney injury in experimental states 
of chronic or acute kidney function impairment.10-14 
Furthermore, statins influence various signaling 
pathways involving kidney inf lammatory, 
proliferative, and cell-death responses. Thereby, 
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statins exert anti-inflammatory actions in kidney 
tissue.13-18 Kidney antioxidant properties with 
consequent endothelial function regulation of 
kidney vasculature, following statin administration, 
may also account for pleiotropic protection against 
kidney injury. Whereas, some publications indicate 
that administration of statins in high doses may 
itself lead to direct kidney tubular cell toxicity.14-18 
However, data on this subject is scares. This study, 
therefore, was focused to evaluate the efficacy 
of different doses of atorvastatin on gentamicin-
induced kidney injury.
MATERIAL AND METHODS
Animals
In this experimental study, 30 male Wistar rats 
weighing 200 g to 250 g were used and similarly 
handled in the animal house of Isfahan University 
of Medical Sciences, Isfahan, Iran. The animals 
were housed at a controlled environment with 
50% to 60% humidity and temperature of 25 ± 3°C. 
Furthermore, the rats were kept with 12-hour dark-
light cycles (lights on at 7.00 AM) and allowed 
free access to pelleted diet and tap water. They 
were also kept in animal lab at least 1 week prior 
to the experiment. During the experiment, the 
animal’s general health status and activity were 
monitored closely. The project was confirmed by 
the Ethical Committee of Isfahan University of 
Medical Sciences and all animal experimentations 
were conducted in accordance with the National 
Institute of Health guidelines for the careful use 
of laboratory animals. 
Drugs and Chemicals 
Atorvastatin was purchased from Kharazmi 
Pharmaceutical Company (Tehran, Iran) and 
administered intraperitoneally. Gentamicin was 
purchased from Alborz Company (Tehran, Iran). 
The rats received 80 mg/kg body weight per 
day of gentamicin, based on previously reported 
protocols.19,20 Administration of atorvastatin was 
according to a previous study.21
Experimental Design 
In this experimental study, 30 male Wistar rats 
were designated into 6 equal groups and treated as 
follows (all injections were intraperitoneal): group 
1 received gentamicin, 80 mg/kg/d, for 7 days. 
Group 2 received phosphate buffer as the vehicle 
of atorvastatin for 7 days. All rats in groups 3, 
4, and 5 received gentamicin, 80 mg/kg/d, for 7 
days, and then, after a 1-hour interval, atorvastatin 
was injected for 7 days as follow: group 3, 10 mg/
kg/d; group 4, 50 mg/kg/d; and group 5, 150 
mg/kg/d. Rats in group 6 received only 150 mg 
of atorvastatin for 7 days. Injections were done 
every day for 7 days, and then on the 8th day, 
all rats were anesthetized using ketamine and 
the blood samples were collected for evaluation 
of creatinine and blood urea nitrogen levels, and 
then all the rats were sacrificed.
Histopathological Examinations
At the end of the experiment, the animals’ kidneys 
were dissected out and fixed in buffered formalin 
for 12 hours and processed for histopathological 
examinations. Three micrometer-thick paraffin 
sections were stained with hematoxylin and 
eosin for light microscopic examination using a 
conventional protocol.22
Histopathological studies were performed under 
a light microscope. Slides were coded and examined 
by a nephropathologist who was blinded to the 
treatment groups. All specimens were examined 
for morphologic parameters including epithelial 
cell degeneration, vacuolization, tubular dilatation, 
tubular cell flattening, and presence of hyaline 
cast and debris materials in the tubular lumen.22
Statistical Analysis
All numerical variables with a normal distribution 
were expressed as mean ± standard deviation and 
categorical variables were presented as absolute 
frequency and percentage. A new variable of 
score was generated by means of histopathology 
evaluations of degeneration, vacuolization, tubular 
dilatation, tubular cell flattening, and presence of 
hyaline cast and debris of injury to the renal tubular 
cells. According to normal data distribution, the 
1-way analysis of variance and post hoc Bonferroni 
tests were used for the comparison of mean values 
between the groups. Data analysis was done using 
the Stata (version 12.0, StataCorp LP, College 
Station, TX, USA). P values less than .01 were 
assumed to be significant. 
RESULTS
The mean of scores of injury to the renal tubular 
cells were 45.2 ± 8.8 in group 1 and 20.1 ± 3.2, 
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20.6 ± 3.9, and 21.6 ± 4.1 in groups 2, 3, and 4, 
respectively. The mean scores of injury to renal 
tubular cells in groups 5 and 6 were 25.8 ± 12.7 
and 53.6 ± 14.9, respectively. The morphological 
damages to the tubular cells in groups 2 and 3 
were less than those in groups 1 and 4 (Table 1). 
Injuries to the tubular cells in the rats which 
received 80 mg/kg of gentamicin and 150 mg/kg 
of atorvastatin were more extensive than those in 
group 1 (80 mg/kg of gentamicin alone; P < .001). 
There was no significant difference of mean scores 
of renal injury between groups 2 and 3 (Table 2). 
In addition, injuries to the tubular cells in the 
rats of group 6, which received only 150 mg of 
atorvastatin were more extensive than those in 
group 1 (80 mg/kg of gentamicin alone) and group 
2 (the control group; P < .001). 
The analysis of blood urea nitrogen and creatinine 
showed greater loos of function in group 4, in 
comparison with group 1 (P < .001; Table 3). These 
findings were in accordance with the morphologic 
findings of the tissue. The mean serum creatinine 
in group 1 was 1.01 ± 0.34 mg/dL, which reached 
to 0.29 ± 0.23 mg/dL and 0.18 ± 0.07 mg/dL after 
receiving atorvastatin with doses of 10 m/kg 
and 50 mg/kg, respectively. The serum values 
of creatinine in groups 5 and 6 were 0.55 ± 0.05 
mg/dL and 1.45 ± 0.96 mg/dL, respectively, the 
latter of which was the highest value among all 
groups (Table 4).
DISCUSSION
Comparison of the administration effects of 
gentamicin (80 mg/kg) alone and co-administration 
of gentamicin and atorvastatin with various doses of 
10 mg/kg and 50 mg/kg revealed that atorvastatin 
was able to effectively reduce the biochemical and 
histopathological alterations of gentamicin-induced 
Score Groups F Statistic* P
I II III IV V VI
Vacuolization 76.0 ± 14.6 5.0 ± 7.0 20.6 ± 6.0 18.3 ± 7.5 55.0 ± 25.0 82.5 ± 9.3 35.41 < .001
Degeneration 81.0 ± 9.0 5.0 ± 7.7 31.6 ± 9.0 39.2 ± 10.0 50.0 ± 22.8 85.0 ± 7.0 30.62 < .001
Debris 40.0 ± 13.0 1.1 ± 2.0 30.8 ± 4.9 30.4 ± 7.4 22.5 ± 13.3 51.6 ± 23.8 10.51 < .001
Dilatation 45.0 ± 21.0 0.7 ± 1.0 14.2 ± 7.0 20.8 ± 10.0 9.5 ± 6.0 58.3 ± 14.0 20.25 < .001
Total score 45.2 ± 8.8 20.1 ± 3.2 20.6 ± 3.9 21.6 ± 4.1 25.8 ± 12.7 53.6 ± 14.9 24.69 < .001
Table 1. Scores for Dilatation, Degeneration, Vacuolization, and Debris of Renal Tubular Cells
*One-way analysis of variance for comparison groups
Score Score Differences Between Groups
1 and 2 1 and 3 1 and 4 1 and 5 1 and 6 2 and 3 2 and 4 2 and 5
Vacuolization 71.0* 55.3* 57.6* 21.0 6.5 15.6 13.3 50.0*
Degeneration 76.0* 49.3* 41.8* 31.0* 4.0 26.6* 34.1* 45.0*
Debris 38.8* 9.1 9.6 17.5 11.6 29.6* 29.2* 21.3
Dilatation 44.3* 30.8* 24.1* 35.5* 13.3 13.5 20.1 8.8
Total score 43.1* 24.5* 23.6* 19.3* 8.4 18.5 19.5* 23.8*
2 and 6 3 and 4 3 and 5 3 and 6 4 and 5 4 and 6 5 and 6
Vacuolization 77.5* 2.3 34.3* 61.3* 36.6* 64.1* 27.5*
Degeneration 80.0* 7.5 18.3 53.3* 10.8 45.8* 35.0*
Debris 50.5* 0.4 8.3 20.8 7.9 21.2 29.1*
Dilatation 57.6* 6.6 4.6 44.1* 11.3 37.5* 48.8*
Total score 51.5* 1.0 5.2 33.0* 4.2 32.0* 27.7*
Table 2. Between-group Comparisons of Dilatation, Degeneration, Vacuolization, and Debris of Renal Tubular Cells
*Significant (P < .01)
Parameter Groups F Statistic* P
I II III IV V VI
Blood urea nitrogen, mg/dL 84.0 ± 52.0 49.3 ± 56.0 98.5 ±19.0 82.2 ± 8.3 60.8 ± 8.4 210.3 ± 64.0 11.33 < .001
Serum creatinine, mg/dL 1.01 ± 0.34 0.26 ± 0.29 0.29 ± 0.23 0.18 ± 0.07 0.55 ± 0.05 1.45 ± 0.96 7.54 < .001
Table 3. Kidney Function Tests Results
*One-way analysis of variance for comparison groups
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cause renal toxicity, which results in brush border 
network injury.30,31 The kidney toxicity involves 
renal free radical production and accumulation, 
consumption of antioxidant defense mechanisms, 
and acute renal tubular necrosis, leading to abolished 
creatinine clearance and kidney dysfunction.30,31 The 
pathological mechanisms also involve an increase 
of endothelin-1, upregulation of transforming 
growth factor-β, significant increase in monocyte/
macrophage infiltration into the kidney cortex and 
medulla, augmentation of oxidative stress, and 
finally apoptosis and consequently necrosis.30,31 
In this study, gentamicin in group 1 effectively 
perturbed kidney function and structure compared 
to the control group. 
Statins have been shown to reduce lipoprotein 
oxidation and ameliorate free radical injury, and 
atorvastatin possesses significant antioxidant 
act ivi ty  against  hydroxyl  free  radical  and 
peroxyl radicals.1-5,16,18 Furthermore, metabolites 
of atorvastatin reduce lipoprotein oxidation in 
a number of oxidative systems. Additionally, 
it was detected that simvastatin diminished 
cisplatin-induced kidney injury by prevention 
of lipid peroxidation.32 Previous investigations 
detected that statins diminished reactive oxygen 
species and superoxide anion kidney production 
either by downregulation of nicotinamide adenine 
dinucleotide phosphate oxidase activity or through 
a decrease in the kidney endothelial expression of 
inducible nitric oxide synthase.1-5,16,18,32 Previous 
in vitro and in vivo results indicated that statins 
suppress the synthesis of inflammatory mediators, 
such as tumor necrosis factor-α. Likewise it was 
observed that simvastatin and pravastatin decreased 
tumor necrosis factor-α and myeloperoxidase 
through mevalonate-independent pathways.16,18,32,33 
Inhibition of increased myeloperoxidase activity 
may result in decreased inducible nitric oxide 
synthase overexpression and subsequently lesser 
generation of reactive oxygen and nitrogen 
renal injury. In this study, there were no significant 
differences between 10 mg/kg and 50 mg/kg dosages 
for renal protective effect of atorvastatin. However, 
administration of 150 mg/kg of atorvastatin was 
not effective to improve the tubular cell damage of 
gentamicin, and even it aggravated tubular damage 
of gentamicin. Moreover, administration of 150 mg 
of atorvastatin alone was toxic for the renal tubular 
cells. This study showed that co-administration of 
gentamicin and high doses of atorvastatin might 
have additive renal toxic effects, and drug interaction 
may perturb kidney function and structure. 
The pathogenesis of acute kidney injury is 
complex, and promoting factors may be completely 
different (ischemia or toxins are main factors 
that precipitate in the damage), however, similar 
pathways may be involved in subsequent damage 
responses.23-26 For this reason, to investigate the 
acute kidney injury models, various methods have 
been described for each specific situation.27,28 The 
none–dose-dependent effect of atorvastatin in 
inducing renal tubular cell protection in this study 
and renal tubular toxicity of atorvastatin in higher 
doses may suggest administration of low-dose 
atorvastatin in critical conditions associated with 
renal tubular cell protection. However, the effect 
of atorvastatin or other statins on other renal toxic 
agents needs more investigation. In this regard, a 
clinical investigation of the effects of atorvastatin 
in prevention of contrast media-induced acute 
kidney injury in patients with chronic kidney 
disease showed that a single high loading dose 
of atorvastatin (80 mg within 24 hours before 
contrast media) administered within 24 hours before 
contrast media exposure was able to reduce the 
rate of contrast media-induced acute kidney injury. 
However, this beneficial effect was observed only 
in patients at low to medium risk.29
Gentamicin has a potential for treating aerobic 
gram-negative bacteria.30 Accumulation of 
gentamicin in the proximal renal tubular cells may 
Parameter Parameter Differences Between Groups
1 and 2 1 and 3 1 and 4 1 and 5 1 and 6 2 and 3 2 and 4 2 and 5
Blood urea nitrogen, mg/dL 34.6 14.5 1.7 23.1 126.3* 49.1 32.9 11.5
Serum creatinine, mg/dL 0.74 0.71 0.82 0.45 0.44 0.02 0.08 0.28
2 and 6 3 and 4 3 and 5 3 and 6 4 and 5 4 and 6 5 and 6
Blood urea nitrogen, mg/dL 161.0* 16.2 37.6 111.8* 21.4 128.1* 149.5*
Serum creatinine, mg/dL 1.18* 0.11 0.25 1.15* 0.36 1.26* 0.90*
Table 4. Between-group Comparisons of Kidney Function Test Results
*Significant (P < .01)
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species.16,18,32,33 In a similar preclinical study, the 
kidney function tests and histopathological and 
immunohistochemical pictures were improved in 
correlation with antioxidant capacity. Atorvastatin 
acts in the kidney as a potent scavenger of free 
radicals to prevent the toxic effects of gentamicin via 
the inhibition of mitogen-activated protein kinase 
and nuclear factor kappa B signaling pathways 
and inducible nitric oxide synthase expression.16 
Atorvastatin decreases cholesterol level by 
inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl-
CoA reductase; however, it has been suggested that 
the clinical profits of statin therapy may be due to 
mechanisms independent of cholesterol lowering 
property.2-5 These pleotropic impacts of statins 
include antioxidant activity, anti-inflammatory 
activity, ability to offer plaque stability and inhibit 
platelet aggregation, and also anti-proliferative and 
immunosuppressive possessions.2-5,13,15 Moreover, 
some evidence denotes that dyslipidemia plays a 
role in introducing and sustaining chronic kidney 
failure. Furthermore, atorvastatin applies cellular 
antioxidant effects in cultured rat vascular smooth 
muscle cells.34 In a comparative study to test 
the incidence of contrast-induced nephropathy 
between atorvastatin and  rosuvastatin,  the 
authors found that atorvastatin and rosuvastatin 
had similar effectiveness in preventing contrast-
induced nephropathy in patients with ST-segment 
elevation myocardial infarction undergoing primary 
coronary angioplasty.5 Accordingly it was found 
that atorvastatin was a protective adjuvant against 
doxorubicin toxicity, by antioxidant, antinitrosative, 
anti-inflammatory, and anti-apoptotic mechanisms.18 
In a nationwide retrospective cohort study, it was 
also reported that statins with high cholesterol-
lowering efficacy might increase the risk for 
developing severe kidney failure.35 It was suggested 
that the nephroprotection against the gentamicin 
nephrotoxicity offered by atorvastatin is mediated 
by scavenging gentamicin-generated free radicals 
through the inhibition of mitogen-activated protein 
kinase and nuclear factor kappa B signaling 
pathway, in addition to inducible nitric oxide 
synthase expression. Statins reduce morbidity and 
mortality from coronary heart disease, prevent 
strokes, and possibly reduce kidney disease as the 
result of improved endothelial function, cholesterol 
lowering, reduced inflammation, and reduced 
oxidative stress.1-5 
Side effects such as myalgia and arthralgia 
are  common with  s ta t ins ;  however ,  f rank 
rhabdomyolysis is infrequent.17 Mechanisms of 
kidney toxicity potentially consist of interruption 
of a wide variety of metabolic functions comprising 
membrane glycoprotein composition and fluidity, 
chloride channel  act ivat ion,  and impaired 
mitochondrial function by reduced ubiquinone 
synthesis that may render lipoproteins more 
susceptible to oxidation injury.17,36,36 Kidney injury 
associated with the use of statins is commonly 
due to associated rhabdomyolysis producing 
acute tubular necrosis.17,35,36 To the best of our 
knowledge, direct renal tubular injury by statins 
is infrequent and is limited to few case reports 
and may be related to administration of very high 
doses of this drug.17,35,36 In the present study, the 
administration of high dose of atorvastatin (150 
mg/kg) not only was nephrotoxic when it was 
administrated alone, but also aggravated the 
tubular injury when it was co-administrated at a 
dose of 150 mg/kg with gentamicin. 
CONCLUSIONS
The results of this study showed a none–dose-
dependent effect for atorvastatin in inducing renal 
tubular cell protection. However, higher doses of 
atorvastatin (50 mg/kg and higher) imposed renal 
tubular toxicity when it was administered alone. 
This finding suggests administration of low-dose 
atorvastatin in critical conditions associated with 
renal tubular cell protection, otherwise applying 
higher doses alone or by interaction with other 
drugs may lead to aggravation of kidney function.
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